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RECENT NORWAY RATS STUDIES USING WARFARIN
RICHARD M. POCHE, Genesis Laboratories, Inc., 10122 N.E. Frontage Road, Wellington, Colorado 80549.
ABSTRACT: Warfarin resistance in the Norway rat (Rattus norvegicus) has been studied over the past 30 years. To
determine the status of this resistance phenomenon wild Norway rats were collected from Colorado and Chicago,
Illinois. As reported previously, warfarin resistance in the Chicago area exceeds 50%, while rats from Colorado remain
very susceptible to warfarin. The theory that true genetic resistance may not exist was examined, implying that
geographic variation in intestinal flora contribute to the rapid degradation of warfarin after ingestion, along with
production of sufficient Vitamin K in the bacteria to reverse the effect of warfarin. Antibiotics in combination were
tested with warfarin and demonstrated that efficacy in the laboratory can be increased by using the combination in a bait
form.
KEY WORDS: warfarin resistance, Norway rat, potentiation, antibiotics, efficacy, bacteria
Proc. 18th Vertebr. Pest Conf. (R.O. Baker & A.C. Crabb,
Eds.) Published at Univ. of Calif., Davis. 1998.
INTRODUCTION
The anticoagulant rodenticide warfarin was developed
during the 1940s and quickly took hold as an effective
means of rodent control and replaced many of the more
toxic and acute compounds. By 1958, Boyle (1969)
reported Norway rats (Rattus norvegicus) developed
resistance to warfarin on farms in Scotland. Reports
surfaced within the next 20 years from various parts of
the globe indicating that the compound was losing its
effectiveness. Such genetic resistance was reported from
the United States by Jackson and Kaukeinen (1972).
As a result of these increasing reports of Norway rats'
resistance, more potent second generation anti-coagulants
were developed to overcome the perceived resistance
problems. These newer rodenticide products contained
such compounds as brodifacoum, bromadiolone,
difenacoum, flocoumafen, and difethialone.
During 1995 wild Norway rats were collected from
Chicago and Colorado. These were subjected to the
routine World Health Organization (WHO) screening test
for warfarin resistance (WHO 1982). The purpose of this
study was to determine if Norway rats in the Chicago
area, previously documented as warfarin resistant,
remained resistant to warfarin after the extensive use of
second generation anticoagulants. Although cross
resistance has been reported from various parts of the
globe, an objective was to determine if resistance
remained in Chicago. It was during that time that the
search for other mechanisms involved in warfarin
resistance in rats began. Why was there a perceived
failure of warfarin as a rodenticide? Although Chicago
and Colorado, or Iowa and Colorado, are not
geographically separated, the consideration of what other
mechanism might be involved in the reduced toxicity of
warfarin based on geography remained in question.
Consideration to drug potentiation, or the interaction
of warfarin with other compounds was examined from the
literature. Previous studies have demonstrated the
potentiation of non-steroid anti-inflammatory drugs on
warfarin (Sirdhara and Krishnamurthy 1992). As early as
1974 Lewis et al. (1974) found that phenylbutazone
potentiated anticoagulant effects.
METHODS
Wild Norway rats were trapped using Tomahawk live
traps. Rat infested areas of Chicago suburbs and feedlots
in eastern Colorado were the source of wild rats used in
this study. The areas selected in Chicago had not been
recently baited by the Bureau of Rodent Control.
Likewise, trap sites utilized in Colorado did not have
recent rodent control efforts. Traps were placed in and
around garages, along building walls, and vacant lots and
were baited with a grain bait. Traps were monitored each
morning. In Chicago, trapped animals were brought to
the nearby regional office of the Bureau of Rodent
Control warehouse, dusted with an EPA approved flea
powder and placed in cages individually until transport
back to the Genesis Laboratories facility in Colorado.
Rats were trapped between April 1995 and October 1997.
Rats were acclimated from two to six weeks before
testing. The temperature within the test room was
maintained at approximately 20 to 25°C and a photoperiod
of 12 hours light: 12 dark was maintained for the duration
of the test. The average humidity was maintained
between 25 to 55%.
Liquid Provision of Tetracycline
The WHO testing protocol for warfarin resistance in
Norway rats was used for screening rats in 1995.
Subsequently, since resistance was approximately 50%,
additional rats in 1996 and 1997 were trapped for further
study. Treatment and control groups were established.
Control groups received 50 ppm warfarin-treated cracked
corn for six consecutive days in a no-choice test.
Separate treatment groups of rats were presented with 5
and 20 mg tetracycline per ml of water ad libitum for
three days before presentation of the 50 ppm warfarin
bait. A separate group was given one 750 mg/kg dose of
tetracycline hydrochloride via oral gavage three days
before presentation of the warfarin bait. After obtaining
interesting results in 1996, grain bait were formulated
incorporating antibiotics.
Preparation of Antibiotic Baits
The 0.005% warfarin bait was prepared using a
Hobart Mixer. Cracked corn was used as the carrier.
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An appropriate solvent was used to facilitate proper
mixing of the warfarin in the mix. Baits were prepared
containing of 0.005% warfarin and either tetracycline or
metronidazole at various concentrations.
There were three treatment groups of Norway rats:
warfarin control, warfarin with tetracycline, and warfarin
with metronidazole. A treatment group consisted of eight
Norway rats (four males and four females). Three
replications of each level were subjected to the
experimental design.
The treated baits were offered on six consecutive
days. Each cup contained 40 grams and consumption was
weighed every 24 hours. Consumption was recorded and
additional feed was added so each cup contained 40
grams. At the end of the six-day test period, the test
material was removed and Manna Pro Lab Cubes were
provided ad libitum during the ten-day post-test
observation period.
Observations were recorded twice daily during the
exposure and post-treatment periods. Signs of warfarin
intoxication and mortality were recorded, as well as bait
consumption.
RESULTS AND DISCUSSION
Representative results of the Norway rat warfarin
screening for animals collected from Colorado and
Chicago are presented in Tables 1 through 4. During
1995, 187 (144 males and 43 females) rats were trapped
from Chicago and screened for warfarin resistance. Of
these, 55% survived the 50 ppm warfarin diet presented
for six consecutive days.
Fifty-three Norway rats collected from Colorado were
examined for warfarin resistance. All rats died after the
six-day exposure. These data support previous claims that
the Chicago Norway rat population was genetically
resistant to warfarin while rats from Colorado were
non-resistant.
Norway rats given tetracycline-treated water for three
days before presentation of 50 ppm warfarin diet were
more susceptible to the bait (Table 5). Mortality in the
control groups, those rats fed 50 ppm warfarin without
the antibiotic, averaged 54.3%; while the treated groups
receiving 5 and 20 mg per ml, respectively, attained 90%
mortality.
The group of rats gavaged once with 750 mg/ml
tetracycline then exposed to a 50 ppm warfarin diet did
not respond in a similar manner. Mortality was only
60%, indicating that repeated doses were more efficacious
in depleting the intestinal flora.
During 1997, additional research was conducted on
tetracycline and metronidazole treated (Borchert 1997).
A summary table of that study is presented in Table 6.
Test groups treated with warfarin control, warfarin plus
tetracycline, and warfarin with metronidazole additive,
resulted in mortality of 74.1, 92.6, and 92.6%,
respectively. There was no significant difference in
consumption for the three formulations tested.
The results of adding certain antibiotics to warfarin
indicate that efficacy can be enhanced when controlling
Norway rats. Test groups exposed to 50 ppm warfarin
including an antibiotic achieved high mortality. In the
past, the nominal concentration of most warfarin baits
sold in the U.S. was 250 ppm, more than adequate a
concentration to attain effective Norway rat control.
Drug interactions with warfarin have been reported
previously and the number of compounds that potentiate
the effects are numerous (Wells et al. 1994). The exact
mechanisms involved, however, remain nebulous.
The addition of tetracycline and metronidazole, as
well as other antibiotics to warfarin, increases the toxicity
over warfarin alone and is attributed the bacteria in the
intestinal tract. Although previous studies indicated that
earlier forms of antibiotics did not appreciably affect the
efficacy of warfarin (Derse 1963), newer and stronger
antibiotics are more efficacious in eliminating gut
bacteria. It is felt that the mechanism in this case
involves the action of the antibiotic on the intestinal flora
of the Norway rat. Geographic variation within species
and number of bacteria results in differing impact on the
reaction to chemicals entering the gastrointestinal tract of
the rat, and possibly the mouse. Warfarin is a relatively
unstable compound and degrades into less toxic
metabolites. The half-life in the gastro-intestinal tract is
a mere 42 hours (Ford 1993). Dupont (1996) reported
the effective half-life of approximately 40 hours. About
92% of the parent compound is excreted in the urine with
a small percentage being the parent material.
Once reaching the gut of the rat, warfarin bait begins
to degrade, based on the types of bacteria present. The
degradation rate in areas such as Chicago influences the
amount of parent compound available for absorption into
the rodent system.
Warfarin elimination is almost entirely by metabolism
by hepatic microsomal enzymes to inactive hydroxyiated
metabolites by reductases to reduce metabolites (warfarin
alcohols). The warfarin alcohols have minimal
anticoagulant activity (DuPont 1996). The metabolites are
principally excreted into the urine and to a lesser extent
into the bile. The metabolites of warfarin have identified
and include dehydrowarfarin, two diastereoisomer
alcohols: 4'-, 6-, 7-, 8-, and 10-hydroxywarfarin.
Bacteria capable of producing more vitamin K, the
antidote for warfarin, also contributes to the reduced
toxicity of warfarin in certain populations of Norway rats.
It is suggested that a combination of factors involving the
degradation of warfarin by bacteria and the production of
vitamin K by the intestinal flora contribute to reduced
toxicity of the rodenticide. This geographic variation in
the ability of Norway rats to tolerate warfarin, is probably
attributed to regional differences in intestinal flora
species. The issue of Norway rat genetic resistance to
warfarin in the U.S. requires careful re-examination
again, especially in light of the regulatory restrictions
being placed on more toxic anticoagulants.
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Table 3. Results of warfarin resistance screening test for Norway rats
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 Three-day exposure to tetracycline in water.
2
 Single oral gavage.
Table 6. Results of laboratory tests on Norway rats fed 0.005% warfarin diet as control, and diet treated with
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